ClinicalTrials.gg
CompletedNCT00761202Updated Nov 19, 2013Results posted

Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms

A Phase 4 interventional study of A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE® and Sodium hyaluronate in Dry Eye Syndromes, sponsored by Allergan. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-19.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Hyaluronic Acid · Dry Eye Syndromes.

Enrollment
13th of 18
50 · median 88
Started
2007
with 1 other
Phase 4
5 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
3 of 18
Allergan

Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, this one is the 13th largest by enrollment, is one of 2 that started in 2007, is one of 5 in phase 4, and was the 2nd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This study evaluates the performance and acceptance of Optive versus Hylocomod eyedrops, when administered for one month to patients with mild to moderate dry eye symptoms, with and without contact lenses.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or over
  • Contact lens wearer, spectacle wearer or non-spectacle wearer
  • Mild to severe dry eye symptoms, defined as OSDI score 13 to 100
  • Mild to moderate conjunctival staining in each eye and/or mild to moderate corneal staining in each eye
  • Best corrected visual acuity of 6/9 in each eye

Exclusion criteria

Exclusion Criteria:

  • Previously used Hylocomod or Optive eyedrops
  • Systemic allergy or eye allergy
  • Systemic disease which might have an ocular component and/or interfere with contact lens wear
  • disease which might have an ocular component and/or interfere with contact lens wear
  • Systemic medication which might have eye side effects and or interfere with contact lens wear
  • Eye infection or use of eye medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    1

    Optive Eyedrops

    Drug: A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®

  • Active comparator
    2

    Hylocomod Eyedrops

    Drug: Sodium hyaluronate

Interventions

  • DrugA sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®

    Eyedrops as required, but at least 3 times per day

    Also known as: Optive™ Eyedrops

  • Eyedrops as required, but at least 3 times per day

    Also known as: Hylocomod

06

What researchers measure

Primary outcomes

  1. Conjunctival Staining by Lissamine Green

    Percentage of cases of limbal staining by lissamine green at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)

    Time frame: week 1, month 1

Secondary outcomes

  1. Corneal Staining by Fluorescein

    Percentage of cases of limbal staining by sodium fluorescein at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)

    Time frame: week 1, month 1

  2. Conjunctival Hyperaemia

    Percentage of conjunctival response reported in terms of limbal hyperaemia for the worst responses over the area at each point on a five point scale (0=clear/white conjunctiva, 1=slight redness, 2=Mild redness, 3=Moderate redness, 4=Severe redness)

    Time frame: week 1, month 1

  3. Ocular Comfort and Ocular Symptoms on Visual Analogue Scale

    Mean comfort judged on a 100 point visual analogue scale (0=Very Poor, 100=Excellent)

    Time frame: week 1, month 1

  4. Daily Eyedrop Usage

    Average daily eyedrop use

    Time frame: Month 1

  5. Lipid Layer Pattern Assessment

    Lipid layer thickness as determined by lipid layer mixing pattern. A high mixing pattern = thick lipid layer.

    Time frame: Week 1, month 1

07

Results

Posted Feb 4, 2010

Participant flow

Participant flow — Overall Study
MilestoneCarboxymethylcellulose and GlycerinSodium Hyaluronate
Started2228
Completed2126
Not completed12

Outcome measures

PrimaryConjunctival Staining by Lissamine Green

Percentage of cases of limbal staining by lissamine green at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)

Time frame:
week 1, month 1
Reported as:
Number · Percentage of Participants
Conjunctival Staining by Lissamine Green
Percentage of ParticipantsCarboxymethylcellulose and GlycerinSodium Hyaluronate
Week 1 - None50.053.8
Week 1 - Trace17.515.4
Week 1 - Mild17.525.0
Week 1 - Moderate15.05.8
Week 1 - Severe0.00.0
Month 1 - None78.650.0
Month 1 - Trace11.917.3
Month 1 - Mild9.525.0
Month 1 - Moderate0.07.7
Month 1 - Severe0.00.0
SecondaryCorneal Staining by Fluorescein

Percentage of cases of limbal staining by sodium fluorescein at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe)

Time frame:
week 1, month 1
Reported as:
Number · Percentage of Participants
Corneal Staining by Fluorescein
Percentage of ParticipantsCarboxymethylcellulose and GlycerinSodium Hyaluronate
Week 1 - None45.057.7
Week 1 - Trace25.015.4
Week 1 - Mild15.025.0
Week 1 - Moderate15.01.9
Week 1 - Severe0.00.0
Month 1 - None73.851.9
Month 1 - Trace21.415.4
Month 1 - Mild4.826.9
Month 1 - Moderate0.05.8
Month 1 - Severe0.00.0
SecondaryConjunctival Hyperaemia

Percentage of conjunctival response reported in terms of limbal hyperaemia for the worst responses over the area at each point on a five point scale (0=clear/white conjunctiva, 1=slight redness, 2=Mild redness, 3=Moderate redness, 4=Severe redness)

Time frame:
week 1, month 1
Reported as:
Number · Percentage of Participants
Conjunctival Hyperaemia
Percentage of ParticipantsCarboxymethylcellulose and GlycerinSodium Hyaluronate
Week 1 - Clear/White5.03.8
Week 1 - Slight75.059.6
Week 1 - Mild17.536.5
Week 1 - Moderate2.50.0
Week 1 - Severe0.00.0
Month 1 - Clear/White0.00.0
Month 1 - Slight71.471.2
Month 1 - Mild28.628.8
Month 1 - Moderate0.00.0
Month 1 - Severe0.00.0
SecondaryOcular Comfort and Ocular Symptoms on Visual Analogue Scale

Mean comfort judged on a 100 point visual analogue scale (0=Very Poor, 100=Excellent)

Time frame:
week 1, month 1
Reported as:
Mean · Units on a scale
Ocular Comfort and Ocular Symptoms on Visual Analogue Scale
Units on a scaleCarboxymethylcellulose and GlycerinSodium Hyaluronate
Ocular Comfort - Waking (Wk.1)67.05 ± 24.9058.81 ± 24.73
Ocular Comfort - Daytime (Wk.1)63.20 ± 22.0568.21 ± 19.48
Ocular Comfort - Evening (Wk.1)57.15 ± 26.3063.38 ± 23.71
Ocular Comfort - Waking (Mo.1)65.05 ± 23.4863.56 ± 28.79
Ocular Comfort - Daytime (Mo.1)68.57 ± 17.2570.48 ± 23.21
Ocular Comfort - Evening (Mo.1)60.38 ± 23.2965.06 ± 23.44
SecondaryDaily Eyedrop Usage

Average daily eyedrop use

Time frame:
Month 1
Reported as:
Mean · drops/day
Daily Eyedrop Usage
drops/dayCarboxymethylcellulose and GlycerinSodium Hyaluronate
Daily Eyedrop Usage3.7 ± 1.43.3 ± 1.0
SecondaryLipid Layer Pattern Assessment

Lipid layer thickness as determined by lipid layer mixing pattern. A high mixing pattern = thick lipid layer.

Time frame:
Week 1, month 1
Reported as:
Median · Lipid Layer Mixing Pattern
Lipid Layer Pattern Assessment
Lipid Layer Mixing PatternCarboxymethylcellulose and GlycerinSodium Hyaluronate
Week 14.50 (0 to 12)5.50 (1 to 10)
Month 13.00 (1 to 10)5.00 (1 to 12)

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboxymethylcellulose and Glycerin—0/21 (0%)2/21 (9.5%)
Sodium Hyaluronate—0/26 (0%)2/26 (7.7%)
Most frequent other events
Most frequent other events
EventCarboxymethylcellulose and GlycerinSodium Hyaluronate
Mild Corneal ToxicityEye disorders1/211/26
Foot InjuryInjury, poisoning and procedural complications1/210/26
Upper Lid CystEye disorders0/211/26

Baseline characteristics

Age Continuous
Age Continuous(years)Carboxymethylcellulose and GlycerinSodium HyaluronateTotal
Mean44.8 ± 16.439.9 ± 14.842.0 ± 16.0
Sex: Female, Male
Sex: Female, Male(Participants)Carboxymethylcellulose and GlycerinSodium HyaluronateTotal
Female162036
Male5611
08

Study locations

1 site
  • London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 29, 2008
Start
Aug 2007
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Feb 4, 2010
Last update
Nov 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00761202
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 29, 2008
Start date
Aug 2007
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Feb 4, 2010
Last update
Nov 19, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion